biostudies-literatureGraf SANational Cancer InstituteNCI NIH HHS176-181https://www.ebi.ac.uk/biostudies/studies/S-EPMC7904587biostudies-literatureUnknown21(3)<h4>Background</h4>Histologic transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment.<h4>Patients and methods</h4>We prospectively evaluated ibrutinib monotherapy in pathologically documented patients with R/R tDLBCL in a single-arm study. The primary endpoint was overall response rate.<h4>Results</h4>Twenty patients who had received a median of 4 (range, 2-9) prior lines of therapy overall (median, 2.5; range, 1-9 for tDLBCL) were treated. The overall response rate was 35%, including complete responses in 15%. The median progression-free survival and overall survival were 4.1 months (95% confidence iClinical lymphoma, myeloma & leukemiaIbrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.PMC7904587P30 CA015704K24 CA184039Krakow ESmith SDLynch RCKanan SSoma LBehnia SRasmussen HChauncey TRVoutsinas JMGraf SAWu QVMorris KGopal AKCassaday RDfalseIbrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.<h4>Background</h4>Histologic transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment.<h4>Patients and methods</h4>We prospectively evaluated ibrutinib monotherapy in pathologically documented patients with R/R tDLBCL in a single-arm study. The primary endpoint was overall response rate.<h4>Results</h4>Twenty patients who had received a median of 4 (range, 2-9) prior lines of therapy overall (median, 2.5; range, 1-9 for tDLBCL) were treated. The overall response rate was 35%, including complete responses in 15%. The median progression-free survival and overall survival were 4.1 months (95% confidence i2021-01-01T00:00:00Z2021 Mar2025-05-18T12:36:35.745Z2025-04-05T10:03:54.415ZS-EPMC79045873335857510.1016/j.clml.2020.11.023